EUVIMEDEUVIMED entdecken
Crossref

Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer

Erina Haraguchi, Takashi Akiyoshi iD, Tatsuki Noguchi, Takashi Sakamoto, Shimpei Matsui, Toshiki Mukai, Tomohiro Yamaguchi, Masamichi Koyama, Senzo Taguchi, Akiko Chino iD, Hiroshi Kawachi, Eiji Shinozaki und 1 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Erina Haraguchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Mutation, Chemoradiotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited data are available on the impact of RAS mutations in patients with locally advanced rectal cancer treated with total neoadjuvant therapy (TNT). This retrospective study aimed to evaluate the effect of RAS mutations on treatment efficacy in 290 patients with locally advanced rectal cancer without distant metastasis, treated between 2015 and 2021 with neoadjuvant long‐course chemoradiotherapy (CRT) with or without neoadjuvant systemic chemotherapy. RAS mutations were analyzed using pretreatment biopsy specimens. Associations between mutations and clinical outcomes were assessed separately in 146 patients who underwent conventional CRT and 144 patients who underwent TNT. RAS mutations were identified in 42.5% and 51.4% of the CRT and TNT groups, respectively. No significant association was observed in either group between RAS mutation and complete response (CR, defined as pathological CR or sustained clinical CR after non‐operative management). However, in the multivariable analysis, RAS mutations were significantly associated with a high neoadjuvant rectal score and worse recurrence‐free survival in the CRT group. Yet, no such associations were observed in the TNT group, suggesting that TNT may mitigate the adverse effects of RAS mutations. Although further prospective, multicenter studies are required, our data suggest that RAS mutations may predict poor responses and higher recurrence risk among patients with locally advanced rectal cancer, and that TNT may be the better treatment option for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsNeoadjuvant TherapyMutationChemoradiotherapyHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultNeoplasm Recurrence, LocalTreatment Outcome

Stichwörter der Autor:innen

RAS mutationsneoadjuvant chemoradiotherapyprognosisrectal cancertotal neoadjuvant therapy

Autor:innen und Institutionen

  • Department of Colorectal Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Rectal Cancer Multidisciplinary Treatment Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Nuclear Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

ORCID-Profile: Takashi Akiyoshi, Akiko Chino

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Haraguchi, E., Akiyoshi, T., Noguchi, T., Sakamoto, T., Matsui, S., Mukai, T., Yamaguchi, T., Koyama, M., Taguchi, S., Chino, A., Kawachi, H., Shinozaki, E., & Yamaguchi, K. (2025). Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70040

Vancouver

Haraguchi E, Akiyoshi T, Noguchi T, Sakamoto T, Matsui S, Mukai T, et al. Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer. International Journal of Cancer. 2025. doi:10.1002/ijc.70040

BibTeX
@article{Haraguchi2025,
  author = {Haraguchi, Erina and Akiyoshi, Takashi and Noguchi, Tatsuki and Sakamoto, Takashi and Matsui, Shimpei and Mukai, Toshiki and Yamaguchi, Tomohiro and Koyama, Masamichi and Taguchi, Senzo and Chino, Akiko and Kawachi, Hiroshi and Shinozaki, Eiji and Yamaguchi, Kensei},
  title = {Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70040}
}
Kostenlos starten →